IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i6p3225-d767485.html
   My bibliography  Save this article

Wolfram Syndrome 1: From Genetics to Therapy

Author

Listed:
  • Luciana Rigoli

    (Department of Human Pathology of Adulthood and Childhood G. Barresi, University of Messina, 98125 Messina, Italy)

  • Valerio Caruso

    (Psychiatry 2 Unit, Clinical and Experimental Medicine Department, University of Pisa, 56126 Pisa, Italy)

  • Giuseppina Salzano

    (Department of Human Pathology of Adulthood and Childhood G. Barresi, University of Messina, 98125 Messina, Italy)

  • Fortunato Lombardo

    (Department of Human Pathology of Adulthood and Childhood G. Barresi, University of Messina, 98125 Messina, Italy)

Abstract

Wolfram syndrome 1 (WS1) is a rare neurodegenerative disease transmitted in an autosomal recessive mode. It is characterized by diabetes insipidus (DI), diabetes mellitus (DM), optic atrophy (OA), and sensorineural hearing loss (D) (DIDMOAD). The clinical picture may be complicated by other symptoms, such as urinary tract, endocrinological, psychiatric, and neurological abnormalities. WS1 is caused by mutations in the WFS1 gene located on chromosome 4p16 that encodes a transmembrane protein named wolframin. Many studies have shown that wolframin regulates some mechanisms of ER calcium homeostasis and therefore plays a role in cellular apoptosis. More than 200 mutations are responsible for WS1. However, abnormal phenotypes of WS with or without DM, inherited in an autosomal dominant mode and associated with one or more WFS1 mutations, have been found. Furthermore, recessive Wolfram-like disease without DM has been described. The prognosis of WS1 is poor, and the death occurs prematurely. Although there are no therapies that can slow or stop WS1, a careful clinical monitoring can help patients during the rapid progression of the disease, thus improving their quality of life. In this review, we describe natural history and etiology of WS1 and suggest criteria for a most pertinent approach to the diagnosis and clinical follow up. We also describe the hallmarks of new therapies for WS1.

Suggested Citation

  • Luciana Rigoli & Valerio Caruso & Giuseppina Salzano & Fortunato Lombardo, 2022. "Wolfram Syndrome 1: From Genetics to Therapy," IJERPH, MDPI, vol. 19(6), pages 1-18, March.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:6:p:3225-:d:767485
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/6/3225/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/6/3225/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Maurizio Delvecchio & Matteo Iacoviello & Antonino Pantaleo & Nicoletta Resta, 2021. "Clinical Spectrum Associated with Wolfram Syndrome Type 1 and Type 2: A Review on Genotype–Phenotype Correlations," IJERPH, MDPI, vol. 18(9), pages 1-12, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Luciana Rigoli & Valerio Caruso & Concetta Aloi & Alessandro Salina & Mohamad Maghnie & Giuseppe d'Annunzio & Olga Lamacchia & Giuseppina Salzano & Fortunato Lombardo & Giuseppe Picca, 2022. "An Atypical Case of Late-Onset Wolfram Syndrome 1 without Diabetes Insipidus," IJERPH, MDPI, vol. 19(4), pages 1-6, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Giuseppina Salzano & Luciana Rigoli & Mariella Valenzise & Roberto Chimenz & Stefano Passanisi & Fortunato Lombardo, 2022. "Clinical Peculiarities in a Cohort of Patients with Wolfram Syndrome 1," IJERPH, MDPI, vol. 19(1), pages 1-9, January.
    2. Francesco Maria Rosanio & Francesca Di Candia & Luisa Occhiati & Ludovica Fedi & Francesco Paolo Malvone & Davide Fortunato Foschini & Adriana Franzese & Enza Mozzillo, 2022. "Wolfram Syndrome Type 2: A Systematic Review of a Not Easily Identifiable Clinical Spectrum," IJERPH, MDPI, vol. 19(2), pages 1-12, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:6:p:3225-:d:767485. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.